Contribute Try STAT+ Today

Amgen said Sunday that patients with advanced lung cancer who were given its drug to block a protein called KRAS lived for a median of six months without their tumors worsening. That’s a measure of response durability that experts say could be strong enough to secure the drug’s approval — if replicated in a larger clinical trial that will read out later this year.

But the Amgen drug, a pill called sotorasib (formerly known as AMG 510) showed partial tumor shrinkage in just over one-third of the lung cancer patients enrolled in the trial. That’s down from a 50% partial response rate reported last year in the same study.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Pancreatic adenocarcinoma frequently has KRAS mutations, but I gather that they typically have a different mutation. It used to be thought that KRAS was “undruggable.” Maybe not. This sounds like a breakthrough.

Comments are closed.